{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T05:02:10Z","timestamp":1739682130666,"version":"3.37.1"},"reference-count":23,"publisher":"Japan Neurosurgical Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol. Med. Chir.(Tokyo)"],"published-print":{"date-parts":[[2025,2,15]]},"DOI":"10.2176\/jns-nmc.2024-0201","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T22:12:10Z","timestamp":1733782330000},"page":"71-80","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial"],"prefix":"10.2176","volume":"65","author":[{"given":"Takafumi","family":"TANEI","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"},{"name":"Department of Specialized Headache Outpatient, Nagoya Garden Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"MAESAWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"NISHIMURA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"ISHIZAKI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"NAGASHIMA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"HASHIDA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"YAMAMOTO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"ANDO","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yachiyo","family":"KUWATSUKA","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"HASHIZUME","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Education, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"WAKABAYASHI","sequence":"additional","affiliation":[{"name":"Department of Specialized Headache Outpatient, Nagoya Garden Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"SAITO","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Nagoya University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Shimizu T, Sakai F, Miyake H, et al.: Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. <i>J Headache Pain<\/i> 2021: 22: 29","DOI":"10.1186\/s10194-021-01243-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hirata K, Ueda K, Komori M, et al.: Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. <i>Curr Med Res Opin<\/i> 2021: 37: 1945-1955","DOI":"10.1080\/03007995.2021.1971179"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ishii R, Schwedt TJ, Kim SK, Dumkrieger G, Chong CD, Dodick DW: Effect of migraine on pregnancy planning: insights from the American registry for migraine research. <i>Mayo Clin Proc<\/i> 2020: 95: 2079-2089","DOI":"10.1016\/j.mayocp.2020.06.053"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Edvinsson L, Ho TW: CGRP receptor antagonism and migraine. <i>Neurotherapeutics<\/i> 2010: 7: 164-175","DOI":"10.1016\/j.nurt.2010.02.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Olesen J, Diener HC, Husstedt IW, et al.: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. <i>N Engl J Med<\/i> 2004: 350: 1104-1110","DOI":"10.1056\/NEJMoa030505"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Durham PL, Vause CV: Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. <i>CNS Drugs<\/i> 2010: 24: 539-548","DOI":"10.2165\/11534920-000000000-00000"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al.: A controlled trial of erenumab for episodic migraine. <i>N Engl J Med<\/i> 2017: 377: 2123-2132","DOI":"10.1056\/NEJMoa1705848"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY: Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. <i>Cephalalgia<\/i> 2018: 38: 1442-1454","DOI":"10.1177\/0333102418779543"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Dodick DW, Silberstein SD, Bigal ME, et al.: Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. <i>JAMA<\/i> 2018: 319: 1999-2008","DOI":"10.1001\/jama.2018.4853"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sakai F, Suzuki N, Kim BK, et al.: Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. <i>Headache<\/i> 2021: 61: 1102-1111","DOI":"10.1111\/head.14178"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Takeshima T, Sakai F, Hirata K, et al.: Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. <i>Headache<\/i> 2021: 61: 927-935","DOI":"10.1111\/head.14138"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Peres MF, Silberstein S, Moreira F, et al.: Patients&apos; preference for migraine preventive therapy. <i>Headache<\/i> 2007: 47: 540-545","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Goadsby PJ, Dodick DW, Martinez JM, et al.: Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. <i>J Neurol Neurosurg Psychiatry<\/i> 2019: 90: 939-944","DOI":"10.1136\/jnnp-2018-320242"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Detke HC, Millen BA, Zhang Q, et al.: Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. <i>Headache<\/i> 2020: 60: 348-359","DOI":"10.1111\/head.13691"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Winner PK, Spierings ELH, Yeung PP, et al.: Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. <i>Headache<\/i> 2019: 59: 1743-1752","DOI":"10.1111\/head.13654"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Takeshima T, Nakai M, Shibasaki Y, et al.: Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b\/3 trials in Japanese and Korean patients. <i>J Headache Pain<\/i> 2022: 23: 24","DOI":"10.1186\/s10194-022-01393-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Schwedt T, Reuter U, Tepper S, et al.: Early onset of efficacy with erenumab in patients with episodic and chronic migraine. <i>J Headache Pain<\/i> 2018: 19: 92","DOI":"10.1186\/s10194-018-0923-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hirata K, Takeshima T, Sakai F, et al.: Early onset of efficacy with erenumab for migraine prevention in Japanese patients: analysis of two randomized, double-blind, placebo-controlled studies. <i>Brain Behav<\/i> 2022: 12: e2526","DOI":"10.1002\/brb3.2526"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Bayliss MS, Dewey JE, Dunlap I, et al.: A study of the feasibility of Internet administration of a computerized health survey: the headache impact test (HIT). <i>Qual Life Res<\/i> 2003: 12: 953-961","DOI":"10.1023\/A:1026167214355"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF: The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. <i>Qual Life Res<\/i> 2013: 22: 1123-1133","DOI":"10.1007\/s11136-012-0230-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Rush AJ, Trivedi MH, Ibrahim HM, et al.: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. <i>Biol Psychiatry<\/i> 2003: 54: 573-583","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Cho S, Kim BK: Long-term outcome after discontinuation of CGRP-targeting therapy for migraine. <i>Curr Pain Headache Rep<\/i> 2024: 28: 743-751","DOI":"10.1007\/s11916-024-01259-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sacco S, Bendtsen L, Ashina M, et al.: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>J Headache Pain<\/i> 2019: 20: 6","DOI":"10.1186\/s10194-018-0955-y"}],"container-title":["Neurologia medico-chirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/2\/65_2024-0201\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T04:30:32Z","timestamp":1739593832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmc\/65\/2\/65_2024-0201\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2024-0201","relation":{},"ISSN":["0470-8105","1349-8029"],"issn-type":[{"type":"print","value":"0470-8105"},{"type":"electronic","value":"1349-8029"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"article-number":"2024-0201"}}